Education
About Us
Working with TipRanks
Follow Us
Quinsam Capital Corporation (TSE:QCA)
:QCA
QCA Stock Chart & Stats
C$0.05
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.05
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.07
Previous CloseN/A
Volume0.00
Average Volume (3M)20.38K
Market Cap
C$4.68M
Enterprise ValueC$3.85M
Total Cash (Recent Filing)C$365.04K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta-0.14
Next Earnings
May 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding93,616,450
10 Day Avg. Volume17,075
30 Day Avg. Volume20,383
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.46
Price to Sales (P/S)-2.21
P/FCF Ratio-8.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetQuinsam's zero total debt is a durable structural strength: it reduces solvency risk, preserves strategic optionality, and allows the firm to deploy capital or withstand portfolio drawdowns without immediate refinancing. This supports long-term survival while pursuing opportunistic investments.
Potential NAV Uplift From ListingsPlanned listings for Peninsula (Renterz) and Electro Metals represent structural catalysts: successful IPOs would crystallize private asset values, improve portfolio liquidity, and sustainably raise NAV. Realized listings can materially shift long-term capital base and reduce valuation opacity.
Clinical-trial Progress For A-SynapticRegulatory approval for a clinical trial and a material grant indicate substantive de-risking and external validation for A-Synaptic. As a portfolio company, successful clinical outcomes or milestone achievements would deliver durable value creation and potential material upside to Quinsam's investment realizations.
Bears Say
Recurring Net LossesSustained multi-year net losses erode equity and reduce internal capital available for reinvestment. For an investment holding company without operating revenue, persistent losses increase dependency on successful exits or external funding and heighten the long-term risk to shareholder capital.
Negative Operating Cash FlowRecent cash burn reduces financial flexibility: negative operating and free cash flows force reliance on portfolio monetizations or financings. Without recurring operating income, ongoing negative cash flow over months could necessitate dilutive raises or asset sales, undermining long-term strategy execution.
Execution & Regulatory Transaction RiskCease-trade events and tax complications on potential deals are structural execution risks for a merchant bank. Such regulatory or transactional impediments can delay value realization, depress valuations of holdings, and add uncertainty to NAV recovery timelines, affecting long-term returns.
Quinsam Capital News
QCA FAQ
What was Quinsam Capital Corporation’s price range in the past 12 months?
Quinsam Capital Corporation lowest stock price was C$0.04 and its highest was C$0.07 in the past 12 months.
What is Quinsam Capital Corporation’s market cap?
Quinsam Capital Corporation’s market cap is C$4.68M.
When is Quinsam Capital Corporation’s upcoming earnings report date?
Quinsam Capital Corporation’s upcoming earnings report date is May 04, 2026 which is in 89 days.
How were Quinsam Capital Corporation’s earnings last quarter?
Quinsam Capital Corporation released its earnings results on Dec 01, 2025. The company reported C$0.001 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.001.
Is Quinsam Capital Corporation overvalued?
According to Wall Street analysts Quinsam Capital Corporation’s price is currently Overvalued.
Does Quinsam Capital Corporation pay dividends?
Quinsam Capital Corporation pays a Quarterly dividend of C$0.001 which represents an annual dividend yield of N/A. See more information on Quinsam Capital Corporation dividends here
What is Quinsam Capital Corporation’s EPS estimate?
Quinsam Capital Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Quinsam Capital Corporation have?
Quinsam Capital Corporation has 93,616,450 shares outstanding.
What happened to Quinsam Capital Corporation’s price movement after its last earnings report?
Quinsam Capital Corporation reported an EPS of C$0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Quinsam Capital Corporation?
Currently, no hedge funds are holding shares in TSE:QCA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Quinsam Capital Corporation
Quinsam Capital Corporation operates as a merchant banking firm in small-cap market in Canada. It primarily focuses on investments in technology, healthcare, mining exploration, e-sports, and cannabis markets. The company's activities include acquisitions, advisory services, lending activities, and portfolio investments. Quinsam Capital Corporation was incorporated in 2004 and is based in Toronto, Canada.
Technical Analysis
Aberdeen International
―
Belgravia Capital International Inc
―
ThreeD Capital
―
Prime Dividend Cl A
―
Zimtu Capital
―
Options Prices
Currently, No data available
---